Healio

Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...

United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public ...
European Medical Journal

Early Lung Decline Identified in Pulmonary Fibrosis

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
Medscape

Less FVC Decline in Progressive PF With Oral Nerandomilast

SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...